Skip to main content
OpenTrials

Clinical trial condition

Hematological Malignancies

Explore clinical trials studying Hematological Malignancies. Study availability and eligibility vary by location and protocol.

102 public trials 22 recruiting studies
Refine in advanced search Browse all conditions

Hematological Malignancies trial results

Active, not recruiting

Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

NCT03145181

Conditions
Hematologic Diseases, Hematologic Neoplasms, Hematological Malignancies, +3 more
Locations
  • City of Hope Duarte, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects New York, United States
  • Levine Cancer Institute Charlotte, North Carolina, United States
View all 13 locations
View Trial Details
Active, not recruiting

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04557098

Conditions
Hematologic Diseases, Hematologic Neoplasms, Hematological Malignancies, +3 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • City of Hope Duarte, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Stanford University Medical Center Stanford, California, United States
View all 51 locations
View Trial Details
Active, not recruiting

Durvalumab and Tremelimumab for Pediatric Malignancies

NCT03837899

Conditions
Hematologic Diseases, Hematologic Neoplasms, Hematological Malignancies, +5 more
Locations
  • Research Site Baltimore, Maryland, United States
  • Research Site Boston, Massachusetts, United States
  • Research Site New Hyde Park, New York, United States
  • Research Site Oklahoma City, Oklahoma, United States
View all 19 locations
View Trial Details
Active, not recruiting

A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)

NCT05347225

Conditions
Hematologic Diseases, Hematologic Neoplasms, Hematological Malignancies, +3 more
Locations
  • Guangdong Provincial People's Hospital-hematology department ( Site 1002) Guangzhou, Guangdong, China
  • SUN YAT-SEN UNIVERSITY CANCER CENTRE-Internal medicine ( Site 1007) Guangzhou, Guangdong, China
  • Henan Cancer Hospital-hematology department ( Site 1003) Zhengzhou, Henan, China
  • Hunan Cancer Hospital ( Site 1004) Changsha, Hunan, China
View Trial Details
Completed

Dose-range Finding Treosulfan-based Conditioning

NCT01063647

Conditions
Hematologic Diseases, Hematologic Neoplasms, Hematological Malignancies, +3 more
Locations
  • Helsinki University Central Hospital Helsinki, Finland
  • Charité University Hospital Berlin Berlin, Germany
  • University Hospital Hamburg Eppendorf Hamburg, Germany
  • 5th Medical Clinic, Clinic North Nuremberg, Germany
View Trial Details

Related conditions